Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glycogen Storage Disease Type II (GSD-II): later-stage trial registry
1 of 5 indexed Glycogen Storage Disease Type II (GSD-II) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Glycogen Storage Disease Type II (GSD-II): 5 US clinical trials tracked, 1 recruiting.
Glycogen Storage Disease Type II (GSD-II) is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Genzyme, a Sanofi Company, running 5 of these trials.
Enrollment posture brief
Registry condition glycogen-storage-disease-type-ii-gsd-ii
OPEN 1 | RECR 20% | LATE 3 | EARLY 1 | RANK #3391 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Glycogen Storage Disease Type II (GSD-II) lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glycogen Storage Disease Type II (GSD-II) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glycogen Storage Disease Type II (GSD-II) is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Glycogen Storage Disease Type II (GSD-II) research.
Genzyme, a Sanofi Company accounts for 5 of 5 trials (100%). 1 distinct sponsors appear on at least one study for this condition label.
-
Most Glycogen Storage Disease Type II (GSD-II) trials plan to enrol fewer than 100 people.
Median target enrolment is 24 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.
-
Glycogen Storage Disease Type II (GSD-II) research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Pompe Pregnancy Sub-Registry
Genzyme, a Sanofi Company
NCT00567073
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease
Genzyme, a Sanofi Company
NCT00158600
Late-Onset Treatment Study Extension Protocol
Genzyme, a Sanofi Company
NCT00455195
Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.
Genzyme, a Sanofi Company
NCT01898364
Growth and Development Study of Alglucosidase Alfa
Genzyme, a Sanofi Company
NCT00486889
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Glycogen Storage Disease Type II (GSD-II) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glycogen Storage Disease Type II (GSD-II) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glycogen Storage Disease Type II (GSD-II) page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Glycogen Storage Disease Type II (GSD-II) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Genzyme, a Sanofi Company sponsors the most Glycogen Storage Disease Type II (GSD-II) trials on record, review their full trial history before evaluating a specific study. See Genzyme, a Sanofi Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glycogen Storage Disease Type II (GSD-II) condition card totals 5 registered trials; most-linked intervention alglucosidase alfa; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.